Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...

H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to InvestingPro data, ...

NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...

Atara Biotherapeutics will be completing its third large-scale layoff in four years after the biotech company announced that it would be shedding 50% of its workforce by the end of June. Atara, a ...

In a regulatory filing, Atara Biotherapeutics (ATRA) disclosed that on January 27, the company announced a reduction in its workforce that will ...

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ: ...

HC Wainwright issued their FY2024 EPS estimates for Atara Biotherapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns forecasts that the ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ('Atara Biotherapeutics, Inc.') ...

Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC ...

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...